HBsAg-Negative, Anti-HBc–Negative Patients Still Have a Risk of Hepatitis B Virus–Related Hepatitis after Autologous Stem Cell Transplantation for Multiple Myeloma or Malignant Lymphoma
3
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose Although hepatitis B surface antigen (HBsAg)–negative, hepatitis B core antibody (anti-HBc)– negative patients are not considered to be at risk for hepatitis B virus (HBV)–related hepatitis, the actual risk remains to be elucidated. This study aimed to evaluate the risk of HBV-related hepatitis in HBsAg-negative, anti-HBc–negative patients receiving autologous stem cell transplantation (ASCT) for multiple myeloma (MM) or malignant lymphoma. Materials and Methods We retrospectively reviewed data from 271 HBsAg-negative patients (161 anti-HBc–negative and 110 anti-HBc–positive at the time of ASCT) who received ASCT for MM or lymphoma. The risk of HBV-related hepatitis was analyzed according to the presence of anti-HBc. HBV serology results at the time of ASCT were compared with those at the time of diagnosis of MM or lymphoma. Results Three patients (two anti-HBc–negative MMs and one anti-HBc–positive MM) developed HBV-related hepatitis after ASCT. The rate of HBV-related hepatitis did not differ among patients with or without anti-HBc status (p=0.843). HBV-related hepatitis more frequently occurred in MM patients than in lymphoma patients (p=0.041). Overall, 9.1% of patients (16.7% with MM and 5.4% with lymphoma) who were HBsAg–negative and anti-HBc–positive at the time of diagnosis had lost anti-HBc positivity during chemotherapy prior to ASCT. Conclusion Our data suggest that HBsAg-negative, anti-HBc–negative patients at the time of ASCT for MM or lymphoma still might be at a risk for HBV-related hepatitis.
Abstract
Purpose Although hepatitis B surface antigen (HBsAg)–negative, hepatitis B core antibody (anti-HBc)– negative patients are not considered to be at risk for hepatitis B virus (HBV)–related hepatitis, the actual risk remains to be elucidated. This study aimed to evaluate the risk of HBV-related hepatitis in HBsAg-negative, anti-HBc–negative patients receiving autologous stem cell transplantation (ASCT) for multiple myeloma (MM) or malignant lymphoma. Materials and Methods We retrospectively reviewed data from 271 HBsAg-negative patients (161 anti-HBc–negative and 110 anti-HBc–positive at the time of ASCT) who received ASCT for MM or lymphoma. The risk of HBV-related hepatitis was analyzed according to the presence of anti-HBc. HBV serology results at the time of ASCT were compared with those at the time of diagnosis of MM or lymphoma. Results Three patients (two anti-HBc–negative MMs and one anti-HBc–positive MM) developed HBV-related hepatitis after ASCT. The rate of HBV-related hepatitis did not differ among patients with or without anti-HBc status (p=0.843). HBV-related hepatitis more frequently occurred in MM patients than in lymphoma patients (p=0.041). Overall, 9.1% of patients (16.7% with MM and 5.4% with lymphoma) who were HBsAg–negative and anti-HBc–positive at the time of diagnosis had lost anti-HBc positivity during chemotherapy prior to ASCT. Conclusion Our data suggest that HBsAg-negative, anti-HBc–negative patients at the time of ASCT for MM or lymphoma still might be at a risk for HBV-related hepatitis.
참고문헌 (23)
- Pei SN, "Risk and prophylaxis strategy of hepatitis B virus reactivation in patients with lymphoma undergoing chemotherapy with or without rituximab", Leuk Lymphoma, 56, pp.1611~1618 (2015)
- Hwang JP, "Management of patients with hepatitis B who require immunosuppressive therapy", Nat Rev Gastroenterol Hepatol, 11, pp.209~219 (2014)
- Lok AS, "Chronic hepatitis B: update 2009", Hepatology, 50, pp.661~662 (2009)
- Hye Jin Kang, "HBV reactivation in a HBsAg-negative patient with multiple myeloma treated with prednisolone maintenance therapy after autologous HSCT", Blood Research, 50(1), pp.51~53 (2015), 대한혈액학회
- Yoshida T, "Reactivation of hepatitis B virus in HBsAg-negative patients with multiple myeloma: two case reports", Int J Hematol, 91, pp.844~849 (2010)
- Yeo W, "Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors", J Med Virol, 62, pp.299~307 (2000)
- European Association for the Study of the Liver, "EASL clinical practice guidelines: management of chronic hepatitis B virus infection", J Hepatol, 57, pp.167~185 (2012)
- Liaw YF, "Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update", Hepatol Int, 6, pp.531~561 (2012)
- Ceneli O, "Hepatitis B-related events in autologous hematopoietic stem cell transplantation recipients", World J Gastroenterol, 16, pp.1765~1771 (2010)
- Guillaume T, "Immune reconstitution and immunotherapy after autologous hematopoietic stem cell transplantation", Blood, 92, pp.1471~1490 (1998)
- Yeo W, "Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab", J Clin Oncol, 27, pp.605~611 (2009)
- Laperche S, "Blood donors infected with the hepatitis B virus but persistently lacking antibodies to the hepatitis B core antigen", Vox Sang, 80, pp.90~94 (2001)
- Ponde RA, "The underlying mechanisms for the 'anti-HBc alone' serological profile", Arch Virol, 155, pp.149~158 (2010)
- Lu S, "The risk of hepatitis B virus reactivation and the role of antiviral prophylaxis in hepatitis B surface antigen negative", hepatitis B core antibody positive patients with diffuse large B-cell lymphoma receiving rituximab-based chemotherapy, 2015, pp.56, 1027~1032
- Hsu C, "Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: a prospective study", Hepatology, 59, pp.2092~2100 (2014)
- Kang SY, "The prevalence of "anti-HBc alone" and HBV DNA detection among anti-HBc alone in Korea", J Med Virol, 82, pp.1508~1514 (2010)
- Yoo JJ, "Efficacy of antiviral prophylaxis in HBsAg-negative, anti-HBc positive patients undergoing hematopoietic stem cell transplantation", Liver Int, 35, pp.2530~2536 (2015)
- Papastergiou V, "Global epidemiology of hepatitis B virus (HBV) infection", Curr Hepatol Rep, 14, pp.171~178 (2015)
- Han JW, "Risk factors and outcomes of hepatitis B virus reactivation in hepatitis B surface antigen negative patients with hematological malignancies", Hepatol Res, 46, pp.657~668 (2016)
- Uhm JE, "Changes in serologic markers of hepatitis B following autologous hematopoietic stem cell transplantation", Biol Blood Marrow Transplant, 13, pp.463~468 (2007)
- Seto WK, "Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study", J Clin Oncol, 32, pp.3736~3743 (2014)
- Liossis SN, "Rituximab-induced B cell depletion in autoimmune diseases: potential effects on T cells", Clin Immunol, 127, pp.280~285 (2008)
- 김혁, "Recent trends in hepatitis B virus infection in the general Korean population", The Korean Journal of Internal Medicine, 28(4), pp.413~419 (2013), 대한내과학회[DOI]